FDA Investigator Sam Pepe
Sam Pepe has conducted inspections on 24 sites in 2 countries as of 29 May 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
24
Last Inspection Date:
29 May 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
Canada
FDA Investigators that have inspected at least one site in common with Sam Pepe:
Alison N Correll,
Alison N Stieg,
Allison A Aldridge, PhD,
Anastasia I Offordile,
Anastasia I Onuorah,
Anastasia M Shields,
Anita R Michael,
Anthony A Charity,
Anthony C Warchut,
Asamoah Asamoah,
Audrey Thereset Uy,
Bijoy Panicker,
Brian D Nicholson,
Brian L Belz,
Brian R Yaun,
Brooke K Higgins,
Burnell M Henry,
Candice C Mandera,
Carrie L Doupnik,
Charles M Edwards,
Christina K Theodorou,
Christine M Whitby, CSO,
Colleen M Damon,
Craig D Zagata,
Cynthia A Palmer,
Daniel J Deciero,
Daniel J Min,
David A Oluwo,
Deborah J Parris,
Debra J Bennett,
Debra L Pagano,
Denise M Digiulio,
Dennis L Doupnik,
Dina K West,
Donald C Obenhuber, PhD,
Douglas A Campbell,
Dr. Gang Wang, PhD,
Edward D Harris,
Eileen A Liu,
Emest F Bizjak,
Eric L Dong, BS,
Erika V Butler,
Fabian Nchaparro Rodriguez,
Gayle S Lawson,
Geoffrey K Kilili,
George J Flynn,
George Pyramides,
Gifford Whitehurst, Jr,
H Ljamilla Selby,
Hala L Selby,
Hala Lj Whetstone,
Heriberto Negron Rivera,
Jaison J Eapen,
James C Illuminati,
James C Maclaughlin,
James M Mason,
Javier E Santos,
Jean Blackston Hill,
Joanne Heim,
Joanne M Hajoway,
Joey C West,
Jonathan G Matrisciano,
Jonathan W Chapman,
Jose M Cayuela,
Joseph L Despins, PhD,
Julianne C Mccullough,
Junho Pak,
Karen A Briggs,
Karthik B Iyer,
Karyn M Campbell,
Katherine Szestypalow,
Kendra L Brooks,
Ko U Min,
Kristen D Evans,
Kristina J Donohue,
Kristina Mjoyce Pittman,
Lance Mde Souza, MBA,
Laura L Staples,
Lawrence Harmon, Jr,
LCDR Debra Emerson,
LCDR Margaret Edi Gennaro,
LCDR Matthew R Mcnew, MPH, REHS/RS,
LCDR Susan E Polifko,
Leon L Crawley,
Linda M Hoover,
Lisa B Orr,
Lisa M Bellows,
Luella J Rossi,
Luis A Dasta,
Marcellinus D Dordunoo,
Marcelo O Mangalindan, Jr,
Marcus A Ray,
Marea K Harmon,
Margaret Faulkner,
Maria A Reed,
Marie A Fadden,
Mary Davis Lopez,
Matthew R Noonan,
Meena Bansal Gupta, PhD,
Melinda L Rice,
Melissa J Garcia,
Michael A Taylor,
Michael Gurbarg,
Michael J Nerz,
Michael L Casner,
Michael R Klapal,
Michele Gottshall,
Michele M Falchek,
Mike M Rashti,
Monika Borkowska,
Nicholas A Violand,
Nikhil Thakur,
Patrick C Klotzbuecher,
Qin Xu,
Rabin N Ghoshal,
Rachael O Oyewole,
Raffi B Papazian,
Robert B Shibuya, MD,
Robert J Maffei,
Robin P Mathew,
Rose Ljean Mary,
Saleem A Akhtar,
Samuel T Walker,
Sharon K Thoma, PharmD,
Simone E Pitts,
Stacie A Woods,
Stephen J Koniers,
Susan F Laska, MS,
Susan M Jackson,
Tammy L Chavis,
Temar Q Williams,
Thomas E Friel,
Thomas R Withers,
Tiffani D Wilson,
Timothy C Grome,
Tonya R Johnson,
Toyin B Oladimeji,
Vesna V Stanoyevitch,
Vlada Matusovsky,
Yiying E Chen,
Yiyue Zhang (nmi), PhD,
Yvesna C Blaise,
Yvonne C Mcknight,
Yvonne C Wood,
Zhongren Wu
Sam Pepe's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| June, 2013 | FDA 483 Response | PEL HEALTHCARE LLC - Form 483R, 2013-06-24 |
| October, 2017 | EIR | Medical Products Laboratories, Inc. - EIR, 2017-10-12 |
| February, 2010 | FDA 483 | Lannett Company, Inc. - Form 483, 2010-02-09 |
| June, 2013 | FDA 483 | PEL HEALTHCARE LLC - Form 483, 2013-06-05 |
| July, 2012 | EIR | Barr Laboratories Inc. - EIR, 2012-07-26 |
| February, 2010 | FDA 483 | Lannett Company, Inc. - Form 483, 2010-02-09 |
| October, 2017 | FDA 483 | Medical Products Laboratories, Inc. - Form 483, 2017-10-12 |
| December, 2017 | FDA 483 | Almac Clinical Services, LLC - Form 483, 2017-12-22 |
| December, 2017 | EIR | Almac Clinical Services, LLC - EIR, 2017-12-22 |
| June, 2013 | EIR | PEL HEALTHCARE LLC - EIR, 2013-06-05 |
| September, 2009 | FDA 483 | Sigmapharm Laboratories, LLC - Form 483, 2009-09-25 |
| June, 2024 | FDA 483 | The Wright Center for Graduate Medical Education IRB - Form 483, 2024-06-28 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more